Lv2
152 积分 2023-08-25 加入
A First-in-Class JAK/ROCK Inhibitor, Rovadicitinib, for Glucocorticoid-Refractory or -Dependent Chronic GVHD
21小时前
已关闭
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study
5天前
已完结
The Selective Endothelin Receptor Antagonist SC0062 in IgA Nephropathy
8天前
已完结
Efficacy and Safety of Ravulizumab in IgA Nephropathy
8天前
已完结
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
8天前
已完结
Atrasentan in Patients with IgA Nephropathy
8天前
已完结
Atrasentan in Patients with IgA Nephropathy
8天前
已完结
Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape
14天前
已完结
GUK1 activation is a metabolic liability in lung cancer
15天前
已完结
Inflammation, proteases and cancer
1个月前
已完结
皖公网安备34019202002308
